Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis

BACKGROUND: Genotyping of melanomas is used to identify patients for treatment with BRAF and MEK inhibitors, but clinical responses are highly variable. This study investigated the utility of protein expression phenotyping to provide an integrated assessment of gene expression programs in BRAF/NRAS...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Cancer
Hlavní autoři: Krisp, Christoph, Parker, Robert, Pascovici, Dana, Hayward, Nicholas K., Wilmott, James S., Thompson, John F., Mann, Graham J., Long, Georgina V., Scolyer, Richard A., Molloy, Mark P.
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6173697/
https://ncbi.nlm.nih.gov/pubmed/30116025
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0227-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky